免疫检查点抑制剂治疗的肝脏毒性管理

免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）在肿瘤领域取得了令人瞩目的疗效，使肿瘤治疗进入免疫治疗的新时代。但随着ICIs的广泛使用，免疫相关不良事件（immune-related adverse events，irAEs）也随之而来。肝脏是人体重要的代谢和消化器官，ICIs引起的肝脏不良事件应引起临床医师的关注。早发现、早诊断、规范治疗是改善预后的关键。本文简述irAEs的发病现状和可能机制，对现有的免疫相关肝脏毒性管理进行总结。

Management of hepatotoxicity related to immune checkpoint inhibitors treatment

Immune checkpoint inhibitors (ICIs) have shown remarkable effect in the treatment of malignant tumor, which has opened a new era of tumor immunotherapy. However, with the wide application of ICIs, non-specific immune activation due to the drugs brought a series of immune-related adverse events (irAEs). Liver is a vital organ of drug metabolism and digestion. Therefore, immune-related hepatotoxicity should be concerned by clinicians. Early detection, early diagnosis, and standard treatment are the key points to improve the prognosis. Here, this review briefly described the incidence and possible mechanism of irAEs, and summarized the present management of immune-related hepatotoxicity.